<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14089">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923466</url>
  </required_header>
  <id_info>
    <org_study_id>VYR-VSV2-101</org_study_id>
    <nct_id>NCT02923466</nct_id>
  </id_info>
  <brief_title>Trial of Intratumoral Administration of Recombinant Vesicular Stomatitis Virus in Patients With Refractory Solid Tumors</brief_title>
  <official_title>Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus (VSV) Genetically Engineered to Express Sodium Iodine Symporter (NIS) and Human Interferon Beta (IFNβ), in Patients With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vyriad, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vyriad, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity
      of intratumoral administration of VSV-IFNβ-NIS in patients with refractory
      advanced/metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of VSV-IFNβ-NIS</measure>
    <time_frame>28 days after VSV-IFNβ-NIS administration for each dose cohort</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Malignant Solid Tumour</condition>
  <arm_group>
    <arm_group_label>VSV-IFNβ-NIS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VSV-IFNβ-NIS</intervention_name>
    <arm_group_label>VSV-IFNβ-NIS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be &gt; 18 years of age on day of signing informed consent.

          -  Have a histologically confirmed diagnosis of an advanced and/or metastatic solid
             tumor that is relapsed and/or refractory to standard therapy, as defined as
             progression on at least one prior line of therapy in the relapsed/metastatic setting
             and no existing options are felt to provide clinical benefit.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.

          -  Adequate hematological, liver and kidney function.

          -  Must be willing to implement contraception throughout study and for 120 days after
             receiving the study drug.

        Exclusion Criteria:

          -  Has been receiving any other investigational agents, chemotherapy, immunotherapy,
             radiotherapy or molecular targeted agents within 4 weeks of the start treatment.

          -  Has a history of a bone marrow or solid organ transplant.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barb H Duckett</last_name>
    <phone>507-398-4598</phone>
    <email>bucket@vyriad.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 3, 2016</lastchanged_date>
  <firstreceived_date>September 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Vesicular Stomatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
